Harvard Bioscience (HBIO) Total Non-Current Liabilities (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Total Non-Current Liabilities data on file, last reported at $66.7 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 5.03% year-over-year to $66.7 million in Q1 2026; TTM through Mar 2026 was $66.7 million, a 5.03% increase from a year earlier, with the FY2025 full-year figure at $65.0 million, up 4.8% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $66.7 million, up from $65.0 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for HBIO reached as high as $81.1 million in Q1 2022 and fell as low as $60.1 million in Q2 2024.
• Historically, Total Non-Current Liabilities has averaged $67.0 million across 5 years, with a median of $64.6 million in 2023.
• Across the five-year window, Total Non-Current Liabilities rose 13.73% in 2022 and declined 14.07% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $72.1 million in 2022, then fell by 12.92% to $62.8 million in 2023, then dropped by 1.22% to $62.0 million in 2024, then climbed by 4.8% to $65.0 million in 2025, then climbed by 2.64% to $66.7 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $66.7 million in Q1 2026, $65.0 million in Q4 2025, and $62.5 million in Q3 2025.